 |
14 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- GCD enzyme (PRX-112) / Protalix
Trial completion, Phase classification, Trial primary completion date: An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (clinicaltrials.gov) - Sep 28, 2016
P2a, N=10, Completed, Sponsor: Protalix
Not yet recruiting --> Completed | Phase classification: P2 --> P2a | Trial primary completion date: Dec 2014 --> Dec 2015
- || Elelyso (taliglucerase alfa) / Pfizer
Trial completion, Trial primary completion date: A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (clinicaltrials.gov) - Sep 11, 2014
P3, N=15, Completed, Sponsor: Protalix
Not yet recruiting --> Completed | Phase classification: P2 --> P2a | Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- GCD enzyme (PRX-112) / Protalix
New P2 trial: An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (clinicaltrials.gov) - Apr 6, 2014
P2, N=10, Not yet recruiting, Sponsor: Protalix
- GCD enzyme (PRX-112) / Protalix
Enrollment change: Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients (clinicaltrials.gov) - Apr 3, 2014
P1, N=16, Completed, Sponsor: Protalix
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 N=12 --> 16
- | GCD enzyme (PRX-112) / Protalix
Trial completion: Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients (clinicaltrials.gov) - Apr 3, 2014
P1, N=16, Completed, Sponsor: Protalix
N=12 --> 16 Recruiting --> Completed
- | Elelyso (taliglucerase alfa) / Pfizer
Enrollment closed: A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (clinicaltrials.gov) - Aug 12, 2013
P3, N=15, Active, not recruiting, Sponsor: Protalix
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- | GCD enzyme (PRX-112) / Protalix
New P1 trial: Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients (clinicaltrials.gov) - Dec 10, 2012
P1, N=16, Completed, Sponsor: Protalix